0001711279-24-000020 | 10-Q | XBRL Viewer

Print Document

Net Income (Loss) Per Share Attributable to Common Stockholders - Additional Information (Detail) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Stock Options and Unvested Restricted Stocks Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common share equivalents outstanding, excluded from the calculation of diluted net loss per common share	154	3,800
Restricted Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common share equivalents outstanding, excluded from the calculation of diluted net loss per common share	78	291

Leases

3 Months Ended

Mar. 31, 2024

Leases [Abstract]

Leases

As of March 31, 2024, future minimum commitments under the Company’s operating leases with lease terms in excess of 12 months were as follows:


(in thousands)	Operating Leases
2024 (remaining nine months)	$	1,157
2025	1,277
2026	1,277
2027	1,300
2028	1,325
Thereafter	9,438
Future minimum operating lease payments	15,774
Less: Interest	(7,879)
Present value of lease liability	$	7,895

As of March 31, 2024 and December 31, 2023, the Company's weighted-average remaining lease term for operating leases was 12.2 years and 12.3 years, respectively, and the Company’s weighted-average discount rate for operating leases was 9.5% as of March 31, 2024 and December 31, 2023.

The components of the Company’s lease expense are as follows:



	Three Months Ended March 31,
(in thousands)	2024		2023
Lease cost:
Operating lease expense	$	299	$	463
Variable lease expense	40		59
Total lease expense	$	339	$	522

Commitments and Contingencies (Detail) $ in Thousands				3 Months Ended		10 Months Ended
Commitments and Contingencies (Detail) $ in Thousands	Jun. 15, 2023 USD ($)	Apr. 28, 2022 USD ($)	Apr. 27, 2022 USD ($) milestone	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2024 USD ($)
Operating Leased Assets [Line Items]
Litigation settlement				$ 12,500	$ 12,500
PeriphaGen
Operating Leased Assets [Line Items]
Litigation settlement	$ 12,500	$ 25,000		12,500	12,500	$ 37,500
Number of milestones \| milestone			3
Litigation settlement, total consideration	$ 75,000
PeriphaGen \| Milestone Three
Operating Leased Assets [Line Items]
Litigation settlement, amount awarded to other party			$ 12,500
Litigation settlement, milestone payments, sales threshold			300,000
PeriphaGen \| Milestone One
Operating Leased Assets [Line Items]
Litigation settlement, amount awarded to other party			12,500	25,000
Litigation settlement, milestone payments, sales threshold			100,000	100,000
PeriphaGen \| Milestone Two
Operating Leased Assets [Line Items]
Litigation settlement, amount awarded to other party			12,500	25,000
Litigation settlement, milestone payments, sales threshold			$ 200,000
PeriphaGen \| Remaining Milestones
Operating Leased Assets [Line Items]
Number of milestones \| milestone			2
Clinical Supply Agreements
Operating Leased Assets [Line Items]
Estimated remaining commitment				1,100		$ 1,100
Project management service fee				$ 1,500	$ 2,000

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Mar. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Revenue Recognition - Allowances And Discounts (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($)
Accounts Receivable, Allowance For Credit Loss [Roll Forward]
Balance as of December 31, 2023	$ 7,114
Provisions	7,522
Payments/Credits	(1,462)
Balance, as of March 31, 2024	13,174
Rebates
Accounts Receivable, Allowance For Credit Loss [Roll Forward]
Balance as of December 31, 2023	5,977
Provisions	5,746
Payments/Credits	(434)
Balance, as of March 31, 2024	11,289
Prompt Pay
Accounts Receivable, Allowance For Credit Loss [Roll Forward]
Balance as of December 31, 2023	858
Provisions	1,565
Payments/Credits	(953)
Balance, as of March 31, 2024	1,470
Other Accruals
Accounts Receivable, Allowance For Credit Loss [Roll Forward]
Balance as of December 31, 2023	279
Provisions	211
Payments/Credits	(75)
Balance, as of March 31, 2024	$ 415

Capitalization - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	Mar. 31, 2024	Dec. 31, 2023	May 08, 2023	Dec. 31, 2020
Schedule of Capitalization, Equity [Line Items]
Common stock, par value (in dollars per share)	$ 0.00001	$ 0.00001		$ 0.00001
Shares issued (in shares)	28,528,000	28,237,000
Placement Shares
Schedule of Capitalization, Equity [Line Items]
Sale of stock, aggregate offering price	$ 150.0			$ 150.0
2020 ATM Program
Schedule of Capitalization, Equity [Line Items]
Shares issued (in shares)	0
New ATM Program
Schedule of Capitalization, Equity [Line Items]
Sale of stock, aggregate offering price			$ 150.0

Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.00001	$ 0.00001
Common stock, shares authorized	80,000,000	80,000,000
Common stock, shares issued	28,528,000	28,237,000
Common stock, shares outstanding	28,528,000	28,237,000

Balance Sheet Components (Tables)

3 Months Ended

Mar. 31, 2024

Balance Sheet Related Disclosures [Abstract]

Schedule of Inventories

Inventory consisted of the following:


(in thousands)	March 31, 2024		December 31, 2023
Raw materials	$	4,489	$	3,154
Work-in-process	6,387		3,204
Finished goods	161		627
Inventory	$	11,037	$	6,985

Schedule of Property and Equipment, Net

Property and equipment, net consisted of the following:


(in thousands)	March 31, 2024		December 31, 2023

Building and building improvements	$	111,232	$	111,180
Leasehold improvements	25,363		25,068
Manufacturing equipment	25,281		24,905
Construction in progress	6,905		7,291
Laboratory equipment	3,064		2,339
Computer equipment and software	1,647		1,614
Furniture and fixtures	1,640		1,632
Total property and equipment	175,132		174,029
Accumulated depreciation	(15,121)		(12,827)
Property and equipment, net	$	160,011	$	161,202

Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following as of March 31, 2024 and December 31, 2023:


(in thousands)	March 31, 2024		December 31, 2023
Accrued litigation settlement	$	12,500	$	—
Accrued construction-in-progress	4,998		5,182
Accrued payroll and benefits	3,433		8,778
Accrued professional fees	2,654		1,810
Other current liabilities	2,613		2,210
Accrued taxes	2,431		2,283
Accrued preclinical and clinical expenses	882		1,248

Total	$	29,511	$	21,511

Balance Sheet Components

3 Months Ended

Mar. 31, 2024

Balance Sheet Related Disclosures [Abstract]

Balance Sheet Components

Inventory

Inventory consisted of the following:


(in thousands)	March 31, 2024		December 31, 2023
Raw materials	$	4,489	$	3,154
Work-in-process	6,387		3,204
Finished goods	161		627
Inventory	$	11,037	$	6,985

Property and Equipment, Net

Property and equipment, net consisted of the following:


(in thousands)	March 31, 2024		December 31, 2023

Building and building improvements	$	111,232	$	111,180
Leasehold improvements	25,363		25,068
Manufacturing equipment	25,281		24,905
Construction in progress	6,905		7,291
Laboratory equipment	3,064		2,339
Computer equipment and software	1,647		1,614
Furniture and fixtures	1,640		1,632
Total property and equipment	175,132		174,029
Accumulated depreciation	(15,121)		(12,827)
Property and equipment, net	$	160,011	$	161,202

Depreciation expense was $1.4 million and $1.1 million for the three months ended March 31, 2024 and 2023, respectively. Depreciation expense capitalized into inventory was $867 thousand and zero for the three months ended March 31, 2024 and 2023, respectively.

In March 2023, the Company received the permanent occupancy permit for its second commercial scale CGMP facility, ASTRA, which allowed the Company to begin utilizing certain portions of the building. As a result, and as qualification of assets occurred through 2023 and the first quarter of 2024, the majority of assets relating to ASTRA were reclassified from construction in progress to leasehold improvements, manufacturing equipment, buildings and building

improvements, furniture and fixtures, or computer equipment and software as it was determined that assets were ready for their intended use. As certain pieces of equipment are not yet qualified, the Company will continue to hold the remaining assets within construction in progress until qualification has been completed and the assets are ready for their intended use. Estimated remaining payments related to ASTRA were $8.0 million as of March 31, 2024 and are recorded in accounts payable and accrued expenses and other current liabilities on the condensed consolidated balance sheets.

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following as of March 31, 2024 and December 31, 2023:


(in thousands)	March 31, 2024		December 31, 2023
Accrued litigation settlement	$	12,500	$	—
Accrued construction-in-progress	4,998		5,182
Accrued payroll and benefits	3,433		8,778
Accrued professional fees	2,654		1,810
Other current liabilities	2,613		2,210
Accrued taxes	2,431		2,283
Accrued preclinical and clinical expenses	882		1,248

Total	$	29,511	$	21,511

Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2024

Revenue from Contract with Customer [Abstract]

Changes in Allowances and Discounts

The following table summarizes changes in allowances and discounts for the three months ended March 31, 2024:


(in thousands)	Rebates		Prompt Pay		Other Accruals		Total
Balance as of December 31, 2023	$	5,977	$	858	$	279	$	7,114
Provisions	5,746		1,565		211		7,522
Payments/Credits	(434)		(953)		(75)		(1,462)
Balance, as of March 31, 2024	$	11,289	$	1,470	$	415	$	13,174

Net Income (Loss) Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Numerator:
Net income (loss)	$ 932	$ (45,297)
Denominator:
Weighted-average common shares outstanding: basic (in shares)	28,295,000	25,712,000
Dilutive effect of stock options and unvested restricted stock (in shares)	996,000	0
Weighted-average common shares outstanding: diluted (in shares)	29,291,000	25,712,000
Net income (loss) per common share: basic (in dollars per share)	$ 0.03	$ (1.76)
Net income (loss) per common share: diluted (in dollars per share)	$ 0.03	$ (1.76)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-10

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

Net Income (Loss) Per Share Attributable to Common Stockholders

3 Months Ended

Mar. 31, 2024

Earnings Per Share [Abstract]

Net Income (Loss) Per Share Attributable to Common Stockholders

Basic net income (loss) per share attributable to common stockholders is calculated by dividing net income (loss) attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) by the weighted-average number of shares of common stock and common stock equivalents outstanding for the period. Common stock equivalents consist of common stock issuable upon (1) exercise of stock options and (2) vesting of restricted stock awards, restricted stock units and performance-based restricted stock units (collectively, “restricted stock”).

For the three months ended March 31, 2024 and 2023, respectively, there were (1) 154 thousand and 3.8 million common stock equivalents outstanding in the form of stock options and (2) 78 thousand and 291 thousand unvested restricted stock, that have each been excluded from the calculation of diluted net income (loss) per common share as their effect would be anti-dilutive.


	Three Months Ended March 31,
(in thousands, except per share data)	2024		2023

Numerator:
Net income (loss)	$	932	$	(45,297)
Denominator:
Weighted-average basic common shares	28,295		25,712
Dilutive effect of stock options and unvested restricted stock	996		—
Weighted-average diluted common shares	29,291		25,712

Net income (loss) per common share—Basic	$	0.03	$	(1.76)
Net income (loss) per common share—Diluted	$	0.03	$	(1.76)

Organization	3 Months Ended
Organization	Mar. 31, 2024
Accounting Policies [Abstract]
Organization	Organization Krystal Biotech, Inc. (the “Company,” or “we” or other similar pronouns) commenced operations in April 2016. In March 2017, the Company converted from a California limited liability company to a Delaware C-corporation, and changed its name from Krystal Biotech LLC to Krystal Biotech, Inc. In June 2018, the Company incorporated a wholly-owned subsidiary in Australia for the purpose of undertaking preclinical and clinical studies in Australia. In April 2019, the Company incorporated Jeune Aesthetics, Inc. (“Jeune Aesthetics”), in Delaware, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies for aesthetic skin conditions. In January 2022, August 2022, December 2022, August 2023, and March 2024 the Company incorporated wholly-owned subsidiaries in Switzerland, Netherlands, France, Germany, and Japan, respectively, for the purpose of establishing initial operations in Europe and Japan for the commercialization of the Company’s product pipeline. We are a fully integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing and commercialization of genetic medicines to treat diseases with high unmet medical needs. Using our patented gene therapy technology platform that is based on engineered herpes simplex virus-1 (“HSV-1”), we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell’s own machinery then transcribes and translates the transgene to treat the disease. Our vectors are amenable to formulation for non-invasive or minimally invasive routes of administration at a healthcare professional’s office or in the patient’s home by a healthcare professional. Our innovative technology platform is supported by two in-house, commercial scale Current Good Manufacturing Practice (“CGMP”) manufacturing facilities. Liquidity As of March 31, 2024, the Company had an accumulated deficit of $268.9 million. Our transition to operating profitability is dependent upon the continued successful commercialization of VYJUVEK as well as successful development, approval, and commercialization of our other product candidates. Management intends to fund future operations through its on hand cash and cash equivalents, revenue generated from the sale of VYJUVEK, the sale of equity, and may also seek additional capital through arrangements with strategic partners, debt financings, or other sources. There can be no assurance that additional funding will be available on terms acceptable to the Company, if at all. The Company is subject to risks common to companies in the biotechnology industry, including but not limited to the failure of product candidates in clinical and preclinical studies, the development of competing product candidates or other technological innovations by competitors, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to commercialize product candidates. The Company expects to incur significant costs to further its pipeline and to expand its commercialization capabilities in advance of the potential global regulatory approvals of VYJUVEK. The Company believes that its cash, cash equivalents and short-term investments of approximately $538.3 million as of March 31, 2024 will be sufficient to allow the Company to fund its planned operations for at least the next 12 months from the date of this Quarterly Report on Form 10-Q.

Balance Sheet Components - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Balance Sheet Related Disclosures [Abstract]
Raw materials	$ 4,489	$ 3,154
Work-in-process	6,387	3,204
Finished goods	161	627
Inventory, Net, Total	$ 11,037	$ 6,985

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 359,006	$ 358,328
Short-term investments	179,253	173,850
Accounts receivable, net	46,467	42,040
Inventory	11,037	6,985
Prepaid expenses and other current assets	6,485	6,706
Total current assets	602,248	587,909
Property and equipment, net	160,011	161,202
Long-term investments	83,996	61,954
Right-of-use assets	6,845	7,027
Other non-current assets	196	263
Total assets	853,296	818,355
Current liabilities
Accounts payable	5,359	4,132
Current portion of lease liability	1,430	1,474
Accrued rebates	11,289	5,977
Accrued expenses and other current liabilities	29,511	21,511
Total current liabilities	47,589	33,094
Lease liability	6,465	6,620
Total liabilities	54,054	39,714
Commitments and contingencies (see note 7)
Stockholders' equity
Common stock; $0.00001 par value; 80,000 shares authorized as of March 31, 2024 and December 31, 2023; 28,528 and 28,237 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively.	0	0
Additional paid-in capital	1,068,436	1,047,830
Accumulated other comprehensive (loss) gain	(299)	638
Accumulated deficit	(268,895)	(269,827)
Total stockholders’ equity	799,242	778,641
Total liabilities and stockholders’ equity	$ 853,296	$ 818,355

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Income Statement [Abstract]

Revenue from Contract with Customer, Product and Service [Extensible Enumeration]

Product [Member]

Product revenue, net

$ 45,250

$ 0

Expenses

Cost, Product and Service [Extensible Enumeration]

Product [Member]

Cost of goods sold

$ 2,419

$ 0

Research and development

10,957

12,288

Selling, general, and administrative

26,058

24,035

Litigation settlement

12,500

Total operating expenses

51,934

48,823

Loss from operations

(6,684)

(48,823)

Other income

Interest and other income, net

7,616

3,526

Net income (loss)

932

(45,297)

Unrealized (loss) gain on available-for-sale securities and other

(937)

^[1]

574

Comprehensive loss

$ (5)

$ (44,723)

Net income (loss) per common share: basic (in dollars per share)

$ 0.03

$ (1.76)

Net income (loss) per common share: diluted (in dollars per share)

$ 0.03

$ (1.76)

Weighted-average common shares outstanding: basic (in shares)

28,295,000

25,712,000

Weighted-average common shares outstanding: diluted (in shares)

29,291,000

25,712,000

[1]	Includes foreign currency translation losses of $62 thousand and $35 thousand for the three months ended March 31, 2024 and 2023, respectively.

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net income (loss)	$ 932	$ (45,297)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Revenue Recognition

3 Months Ended

Mar. 31, 2024

Revenue from Contract with Customer [Abstract]

Revenue Recognition

Following FDA approval on May 19, 2023, the Company began commercial marketing and sales of VYJUVEK throughout the United States and began recognizing revenue in the third quarter of 2023.

The following table summarizes changes in allowances and discounts for the three months ended March 31, 2024:


(in thousands)	Rebates		Prompt Pay		Other Accruals		Total
Balance as of December 31, 2023	$	5,977	$	858	$	279	$	7,114
Provisions	5,746		1,565		211		7,522
Payments/Credits	(434)		(953)		(75)		(1,462)
Balance, as of March 31, 2024	$	11,289	$	1,470	$	415	$	13,174

Rebates and other accruals are included in accrued rebates and accrued expenses and other current liabilities, respectively, on the condensed consolidated balance sheets. Prompt pay is recorded as an allowance against accounts receivable, net on the condensed consolidated balance sheets. Provisions for rebates, prompt pay and other accruals are recorded as a reduction to product revenue on the condensed consolidated statements of operations and comprehensive loss.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-9

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-15

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-13

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org//606/tableOfContent

+ Details

Organization - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Accumulated deficit	$ 268,895	$ 269,827
Cash, cash equivalents and short-term investments	$ 538,300

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References + Details

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events The Company evaluates events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements, to identify matters that require recognition or disclosure. The Company concluded that no subsequent events have occurred, that would require recognition or disclosure in the condensed consolidated financial statements.

Leases - Minimum Commitments (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Leases [Abstract]
2024 (remaining nine months)	$ 1,157
2025	1,277
2026	1,277
2027	1,300
2028	1,325
Thereafter	9,438
Future minimum operating lease payments	15,774
Less: Interest	(7,879)
Present value of lease liability	$ 7,895

Leases - Additional Information (Details)	Mar. 31, 2024	Dec. 31, 2023
Leases [Abstract]
Weighted average remaining lease term	12 years 2 months 12 days	12 years 3 months 18 days
Weighted average discount rate	9.50%	9.50%

Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 359,006	$ 358,328
Gross Unrealized Gains	161	835
Gross Unrealized (Losses)	(259)	(58)
Amortized Cost	622,353	593,355
Aggregate fair value, total	622,255	594,132
Cash and Cash Equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate fair value, total	359,006	358,328
Short-term Marketable Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate fair value, total	179,253	173,850
Long-term Marketable Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate fair value, total	83,996	61,954
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	359,006	358,328
Aggregate Fair Value	359,006	358,328
Level 1 \| Cash and Cash Equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	359,006	358,328
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	263,347	235,027
Gross Unrealized Gains	161	835
Gross Unrealized (Losses)	(259)	(58)
Aggregate Fair Value	263,249	235,804
Level 2 \| Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	18,747	17,124
Gross Unrealized Gains	0	5
Gross Unrealized (Losses)	(7)	(1)
Aggregate Fair Value	18,740	17,128
Level 2 \| Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	115,918	111,824
Gross Unrealized Gains	132	407
Gross Unrealized (Losses)	(69)	(27)
Aggregate Fair Value	115,981	112,204
Level 2 \| U.S. government agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	128,682	106,079
Gross Unrealized Gains	29	423
Gross Unrealized (Losses)	(183)	(30)
Aggregate Fair Value	128,528	106,472
Level 2 \| Short-term Marketable Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate Fair Value	$ 179,253	173,850
Debt securities, available-for-sale, term	1 year
Level 2 \| Short-term Marketable Securities \| Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate Fair Value	$ 18,740	17,128
Level 2 \| Short-term Marketable Securities \| Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate Fair Value	70,182	70,996
Level 2 \| Short-term Marketable Securities \| U.S. government agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate Fair Value	90,331	85,726
Level 2 \| Long-term Marketable Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate Fair Value	83,996	61,954
Level 2 \| Long-term Marketable Securities \| Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate Fair Value	0	0
Level 2 \| Long-term Marketable Securities \| Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate Fair Value	45,799	41,208
Level 2 \| Long-term Marketable Securities \| U.S. government agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate Fair Value	$ 38,197	20,746
Level 2 \| Long-term Marketable Securities \| Minimum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt securities, available-for-sale, term	1 year
Level 2 \| Long-term Marketable Securities \| Maximum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt securities, available-for-sale, term	2 years
Cash and cash equivalents \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 359,006	358,328
Aggregate Fair Value	359,006	358,328
Cash and cash equivalents \| Level 1 \| Cash and Cash Equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 359,006	$ 358,328

Leases (Tables)

3 Months Ended

Mar. 31, 2024

Leases [Abstract]

Schedule of Future Minimum Operating Lease Payments

As of March 31, 2024, future minimum commitments under the Company’s operating leases with lease terms in excess of 12 months were as follows:


(in thousands)	Operating Leases
2024 (remaining nine months)	$	1,157
2025	1,277
2026	1,277
2027	1,300
2028	1,325
Thereafter	9,438
Future minimum operating lease payments	15,774
Less: Interest	(7,879)
Present value of lease liability	$	7,895

Lease, Cost

The components of the Company’s lease expense are as follows:



	Three Months Ended March 31,
(in thousands)	2024		2023
Lease cost:
Operating lease expense	$	299	$	463
Variable lease expense	40		59
Total lease expense	$	339	$	522

Leases - Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended
Leases - Lease Expense (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Mar. 31, 2023
Leases [Abstract]
Operating lease expense	$ 299	$ 463
Variable lease expense	40	59
Total lease expense	$ 339	$ 522

Capitalization	3 Months Ended
Capitalization	Mar. 31, 2024
Equity [Abstract]
Capitalization	Capitalization ATM Program On December 31, 2020, the Company entered into a sales agreement with Cowen and Company, LLC (“Cowen”) with respect to an at-the-market equity offering program (“2020 ATM Program”), under which the Company issued and sold from time to time through Cowen, acting as agent and/or principal, shares of its common stock, par value $0.00001 per share (“Common Stock”), having an aggregate offering price up to $150.0 million (“Placement Shares”). The issuance and sale of the Placement Shares were made pursuant to the Company’s effective “shelf” registration statement on Form S-3 that was filed with the SEC on May 4, 2020 (“2020 Shelf Registration Statement”). During the three months ended March 31, 2023, no shares of Common Stock were issued pursuant to the 2020 ATM Program. The Company’s 2020 Shelf Registration Statement expired on May 4, 2023, and the Company put in place a new at-the-market equity offering program under substantially the same terms as the 2020 ATM Program (“New ATM Program”). Accordingly, on May 8, 2023, the Company entered into a new sales agreement with Cowen to issue and sell shares of the Company’s Common Stock having an aggregate offering price of up to $150.0 million (“New Placement Shares”) from time to time, under which Cowen will act as the Company’s agent and/or principal. The New Placement Shares will be offered and sold pursuant to the Company’s effective shelf registration statement on Form S-3 filed with the SEC on April 6, 2023, and a prospectus supplement relating to the New Placement Shares that was filed with the SEC on May 8, 2023. During the three months ended March 31, 2024, no shares of Common Stock were issued pursuant to the New ATM Program, resulting in $150.0 million available for issuance under the New ATM Program.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

+ Details

Balance Sheet Components - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Supply Commitment [Line Items]
Depreciation expense	$ 1,427,000	$ 1,093,000
Depreciation expense capitalized	867,000	$ 0
ASTRA Facility
Supply Commitment [Line Items]
Contractual obligation	$ 8,000,000

Net Income (Loss) Per Share Attributable to Common Stockholders (Tables)

3 Months Ended

Mar. 31, 2024

Earnings Per Share [Abstract]

Schedule of Net Income (Loss) Per Share Attributable to Common Stockholders


	Three Months Ended March 31,
(in thousands, except per share data)	2024		2023

Numerator:
Net income (loss)	$	932	$	(45,297)
Denominator:
Weighted-average basic common shares	28,295		25,712
Dilutive effect of stock options and unvested restricted stock	996		—
Weighted-average diluted common shares	29,291		25,712

Net income (loss) per common share—Basic	$	0.03	$	(1.76)
Net income (loss) per common share—Diluted	$	0.03	$	(1.76)

Stock-Based Compensation - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2024 USD ($) $ / shares shares	Mar. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2017 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period increase in shares authorized	0.04
Stock options granted (in shares) \| shares	126,742	287,600
Exercised \| $	$ 24,500,000	$ 1,100,000
Inventories
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amount capitalized \| $	724,000	0
Property, Plant and Equipment
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amount capitalized \| $	$ 0	$ 162,000
Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares remaining available for grant \| shares	2,400,000
2017 IPO Stock Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved (in shares) \| shares			900,000
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value per share of options granted (in dollars per share) \| $ / shares	$ 106.92	$ 56.86
Stock Options \| Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense \| $	$ 63,900,000
Estimated weighted average period	2 years 7 months 6 days
Stock Options \| 2017 IPO Stock Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved (in shares) \| shares			900,000
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense \| $	$ 1,600,000
Estimated weighted average period	11 months
Granted (in shares) \| shares	0	0
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense \| $	$ 43,400,000
Estimated weighted average period	3 years 8 months 12 days
Granted (in shares) \| shares	223,890	186,900
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense \| $	$ 19,000,000
Estimated weighted average period	1 year 9 months 18 days
Granted (in shares) \| shares	112,500	60,000
Stock option vesting period	2 years
Eligible to vest	1

Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Balance Sheet Related Disclosures [Abstract]
Accrued litigation settlement	$ 12,500	$ 0
Accrued construction-in-progress	4,998	5,182
Accrued payroll and benefits	3,433	8,778
Accrued professional fees	2,654	1,810
Other current liabilities	2,613	2,210
Accrued taxes	2,431	2,283
Accrued preclinical and clinical expenses	882	1,248
Total	$ 29,511	$ 21,511

Summary of Significant Accounting Policies	3 Months Ended
Summary of Significant Accounting Policies	Mar. 31, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The accompanying interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”). In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company’s financial position and results of operations for the interim periods presented, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company’s previously reported financial position or results of operations. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (“2023 10-K”), as filed with the U.S. Securities and Exchange Commission (“SEC”) on February 26, 2024. Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates in the period these variances become known. Estimates are used in the following areas, among others: variable consideration associated with revenue recognition, stock-based compensation expense, accrued expenses, the fair value of financial instruments and the valuation allowance included in the deferred income tax calculation. Concentration of Credit Risk and Off-Balance Sheet Risk Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents, short-term investments, long-term investments, and accounts receivable, net. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company’s accounts receivable, net and marketable securities, which primarily consist of U.S. government agency securities and treasuries, corporate bonds and commercial paper, potentially subject the Company to concentrations of credit risk. As of March 31, 2024, the credit profile for the Company’s counterparty was deemed to be in good standing and, as such, an allowance for credit losses was not recorded. The Company had one customer for the three months ended March 31, 2024 and no product revenue for the three months ended March 31, 2023. The Company has no financial instruments with off-balance sheet risk of loss. Summary of Significant Accounting Policies See Note 2 to our consolidated financial statements included in our 2023 10-K. There were no material changes to the Company's significant accounting policies during the three months ended March 31, 2024. Recent Accounting Pronouncements There were no accounting pronouncements issued or adopted during the three months ended March 31, 2024 that are expected to have a material impact on the Company’s condensed consolidated financial statements. In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” The purpose of this guidance is to enhance the transparency and usefulness of income tax disclosures and provide comprehensive income tax information, particularly in relation to rate reconciliation and income taxes paid in the U.S. and foreign jurisdictions. This new standard will be effective for fiscal years starting after December 15, 2024, with the option to apply it retrospectively. Early adoption is also allowed. Currently, the Company is assessing the potential impact of this guidance on its consolidated financial statement disclosures.

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating Activities
Net income (loss)	$ 932	$ (45,297)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities
Depreciation	1,427	1,093
Accretion on marketable securities	(802)	(606)
Amortization of operating lease right-of-use assets	182	218
Stock-based compensation expense, net	9,299	10,437
Realized gain on investments	(1,213)	(809)
Other, net	(238)	1
Changes in operating assets and liabilities
Accounts receivable	(4,427)	0
Inventory	(2,238)	0
Prepaid expenses and other current assets	(264)	(126)
Other non-current assets	52	(46)
Lease liability	(199)	(165)
Accounts payable	727	107
Accrued expenses and other current liabilities	(5,162)	(3,463)
Accrued rebates	5,312	0
Accrued litigation settlement	12,500	12,500
Net cash provided by (used in) operating activities	15,888	(26,156)
Investing Activities
Purchases of property and equipment	(1,260)	(5,381)
Purchases of investments	(88,335)	(145,576)
Maturities of investments	63,615	154,520
Net cash (used in) provided by investing activities	(25,980)	3,563
Financing Activities
Proceeds from exercise of stock options, net	15,969	2,223
Net cash provided by financing activities	10,583	1,474
Effect of exchange rate changes on cash and cash equivalents	187	(36)
Net increase (decrease) in cash and cash equivalents	678	(21,155)
Cash and cash equivalents at beginning of period	358,328	161,900
Cash and cash equivalents at end of period	359,006	140,745
Supplemental Disclosures of Non-Cash Investing Activities
Unpaid purchases of property and equipment included in accounts payable and accrued expenses	8,456	11,865
Restricted Stock Units (RSUs)
Financing Activities
Taxes paid related to settlement of restricted stock awards	(4,181)	0
Restricted Stock
Financing Activities
Taxes paid related to settlement of restricted stock awards	$ (1,205)	$ (749)

Fair Value Instruments (Tables)

3 Months Ended

Mar. 31, 2024

Fair Value Disclosures [Abstract]

Summary of Cash, Cash Equivalents and Available-for-Sale Securities

The following tables show the Company’s cash, cash equivalents and available-for-sale securities by significant investment category as of March 31, 2024 and December 31, 2023:


	March 31, 2024

(in thousands)	Amortized Cost		Gross Unrealized Gains		Gross Unrealized (Losses)		Aggregate Fair Value		Cash and Cash Equivalents		Short-term Marketable Securities(1)		Long-term Marketable Securities(2)
Level 1:
Cash and cash equivalents	$	359,006	$	—	$	—	$	359,006	$	359,006	$	—	$	—
Subtotal	359,006		—		—		359,006		359,006		—		—
Level 2:

Commercial paper	18,747		—		(7)		18,740		—		18,740		—
Corporate bonds	115,918		132		(69)		115,981		—		70,182		45,799
U.S. government agency securities	128,682		29		(183)		128,528		—		90,331		38,197
Subtotal	263,347		161		(259)		263,249		—		179,253		83,996
Total	$	622,353	$	161	$	(259)	$	622,255	$	359,006	$	179,253	$	83,996


	December 31, 2023
(in thousands)	Amortized Cost		Gross Unrealized Gains		Gross Unrealized (Losses)		Aggregate Fair Value		Cash and Cash Equivalents		Short-term Marketable Securities(1)		Long-term Marketable Securities(2)
Level 1:
Cash and cash equivalents	$	358,328	$	—	$	—	$	358,328	$	358,328	$	—	$	—

Subtotal	358,328		—		—		358,328		358,328		—		—
Level 2:
Commercial paper	17,124		5		(1)		17,128		—		17,128		—
Corporate bonds	111,824		407		(27)		112,204		—		70,996		41,208
U.S. government agency securities	106,079		423		(30)		106,472		—		85,726		20,746



Subtotal	235,027		835		(58)		235,804		—		173,850		61,954
Total	$	593,355	$	835	$	(58)	$	594,132	$	358,328	$	173,850	$	61,954

(1)The Company’s short-term marketable securities mature in one year or less.

(2)The Company’s long-term marketable securities mature between one year and two years.

Condensed Consolidated Statements of Stockholders' Equity (unaudited) - USD ($)
$ in Thousands

Total

Common Stock

Additional Paid-in Capital

Accumulated Other Comprehensive (Loss)

Accumulated Deficit

Beginning balance (in shares) at Dec. 31, 2022

25,764,000

Beginning balance at Dec. 31, 2022

$ 522,231

$ 0

$ 803,718

$ (728)

$ (280,759)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Issuance of common stock, net, (in shares)

42,000

Issuance of common stock upon exercise of stock options, net

2,208

Shares surrendered for taxes and forfeitures (in shares)

(10,000)

Shares of restricted stock awards surrendered for taxes

(749)

Stock-based compensation

10,599

Unrealized gain (loss) on investments and other

574

^[1]

Net income (loss)

(45,297)

Ending balance (in shares) at Mar. 31, 2023

25,796,000

Ending balance at Mar. 31, 2023

489,566

$ 0

815,776

(154)

(326,056)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Foreign currency translation loss

Beginning balance (in shares) at Dec. 31, 2023

28,237,000

Beginning balance at Dec. 31, 2023

778,641

$ 0

1,047,830

638

(269,827)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Issuance of common stock, net, (in shares)

260,000

Issuance of common stock upon exercise of stock options, net

15,969

Vesting of restricted stock units, net of shares withheld for taxes (in shares)

39,000

Vesting of restricted stock units, net of shares withheld for taxes

(4,181)

Shares surrendered for taxes and forfeitures (in shares)

(8,000)

Shares of restricted stock awards surrendered for taxes

(1,205)

Stock-based compensation

10,023

Unrealized gain (loss) on investments and other

^[1]

(937)

Net income (loss)

932

Ending balance (in shares) at Mar. 31, 2024

28,528,000

Ending balance at Mar. 31, 2024

799,242

$ 0

$ 1,068,436

$ (299)

$ (268,895)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Foreign currency translation loss

$ 62

[1]	Includes foreign currency translation losses of $62 thousand and $35 thousand for the three months ended March 31, 2024 and 2023, respectively.

Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Stock Options Outstanding
Beginning balance (in shares)	2,606,592	3,582,181	3,582,181
Granted (in shares)	126,742	287,600
Exercised (in shares)	(259,581)	(42,021)
Cancelled or forfeited (in shares)	(245,659)	(42,625)
Ending balance (in shares)	2,228,094	3,785,135	2,606,592	3,582,181
Exercisable end of period (in shares)	854,224	961,428
Weighted-average Exercise Price
Beginning balance (in dollars per share)	$ 66.39	$ 61.15	$ 61.15
Granted (in dollars per share)	155.82	81.83
Exercised (in dollars per share)	61.52	53.54
Cancelled or forfeited (in dollars per share)	67.89	65.59
Ending balance (in dollars per share)	71.88	62.75	$ 66.39	$ 61.15
Exercisable end of period (in dollars per share)	$ 61.08	$ 55.08
Weighted-average Remaining Contractual Life (in years)
Weighted-average remaining contractual life (Years)	7 years 8 months 12 days	8 years 6 months	7 years 10 months 24 days	8 years 8 months 12 days
Weighted-average remaining contractual life (Years), exercisable	6 years 9 months 18 days	7 years 7 months 6 days
Aggregate Intrinsic Value
Aggregate intrinsic value, beginning balance, outstanding	$ 150,405	$ 64,880	$ 64,880
Aggregate intrinsic value, ending balance, outstanding	236,279	66,066	$ 150,405	$ 64,880
Exercisable as of March 31, 2024	$ 99,815	$ 24,033

Fair Value Instruments

3 Months Ended

Mar. 31, 2024

Fair Value Disclosures [Abstract]

Fair Value Instruments

The following tables show the Company’s cash, cash equivalents and available-for-sale securities by significant investment category as of March 31, 2024 and December 31, 2023:


	March 31, 2024

(in thousands)	Amortized Cost		Gross Unrealized Gains		Gross Unrealized (Losses)		Aggregate Fair Value		Cash and Cash Equivalents		Short-term Marketable Securities(1)		Long-term Marketable Securities(2)
Level 1:
Cash and cash equivalents	$	359,006	$	—	$	—	$	359,006	$	359,006	$	—	$	—
Subtotal	359,006		—		—		359,006		359,006		—		—
Level 2:

Commercial paper	18,747		—		(7)		18,740		—		18,740		—
Corporate bonds	115,918		132		(69)		115,981		—		70,182		45,799
U.S. government agency securities	128,682		29		(183)		128,528		—		90,331		38,197
Subtotal	263,347		161		(259)		263,249		—		179,253		83,996
Total	$	622,353	$	161	$	(259)	$	622,255	$	359,006	$	179,253	$	83,996


	December 31, 2023
(in thousands)	Amortized Cost		Gross Unrealized Gains		Gross Unrealized (Losses)		Aggregate Fair Value		Cash and Cash Equivalents		Short-term Marketable Securities(1)		Long-term Marketable Securities(2)
Level 1:
Cash and cash equivalents	$	358,328	$	—	$	—	$	358,328	$	358,328	$	—	$	—

Subtotal	358,328		—		—		358,328		358,328		—		—
Level 2:
Commercial paper	17,124		5		(1)		17,128		—		17,128		—
Corporate bonds	111,824		407		(27)		112,204		—		70,996		41,208
U.S. government agency securities	106,079		423		(30)		106,472		—		85,726		20,746



Subtotal	235,027		835		(58)		235,804		—		173,850		61,954
Total	$	593,355	$	835	$	(58)	$	594,132	$	358,328	$	173,850	$	61,954

(1)The Company’s short-term marketable securities mature in one year or less.

(2)The Company’s long-term marketable securities mature between one year and two years.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Stock-Based Compensation

3 Months Ended

Mar. 31, 2024

Share-Based Payment Arrangement [Abstract]

Stock-Based Compensation

In 2017, the Company adopted the 2017 IPO Stock Plan (“Plan”), which governs the issuance of equity awards to employees, certain non-employee consultants, and directors. Initially, the Company reserved 900 thousand shares for issuance under the Plan with an initial sublimit for incentive stock options of 900 thousand shares. On an annual basis, the amount of shares available for issuance under the Plan increases by an amount equal to four percent of the total outstanding shares as of the last day of the preceding calendar year. The sublimit of incentive stock options is not subject to the increase. The Company has historically granted stock options and restricted stock awards (“RSAs”) to its employees. In February 2023, the Company began issuing restricted stock units (“RSUs”) and performance-based restricted stock units (“PSUs” and with RSUs commonly referred to collectively as “restricted stock units”) to certain employees.

Shares remaining available for grant under the Plan were 2.4 million as of March 31, 2024.

Stock Options

The following table summarizes the Company’s stock option activity for the three months ended March 31, 2024:


	Stock Options Outstanding	Weighted-average Exercise Price		Weighted-average Remaining Contractual Life (in years)	Aggregate Intrinsic Value(1) (in thousands)
Outstanding as of December 31, 2023	2,606,592	$	66.39	7.9	$	150,405
Granted	126,742	$	155.82
Exercised	(259,581)	$	61.52
Cancelled or forfeited	(245,659)	$	67.89

Outstanding as of March 31, 2024	2,228,094	$	71.88	7.7	$	236,279
Exercisable as of March 31, 2024	854,224	$	61.08	6.8	$	99,815

(1)Aggregate intrinsic value represents the difference between the closing stock price of our common stock on December 31, 2023 and March 31, 2024, respectively, and the exercise price of outstanding in-the-money options.

The following table summarizes the Company’s stock option activity for the three months ended March 31, 2023:


	Stock Options Outstanding	Weighted-average Exercise Price		Weighted-average Remaining Contractual Life (in years)	Aggregate Intrinsic Value(1) (in thousands)
Outstanding as of December 31, 2022	3,582,181	$	61.15	8.7	$	64,880
Granted	287,600	$	81.83
Exercised	(42,021)	$	53.54
Cancelled or forfeited	(42,625)	$	65.59

Outstanding as of March 31, 2023	3,785,135	$	62.75	8.5	$	66,066
Exercisable as of March 31, 2023	961,428	$	55.08	7.6	$	24,033

(1)Aggregate intrinsic value represents the difference between the closing stock price of our common stock on December 31, 2022 and March 31, 2023, respectively, and the exercise price of outstanding in-the-money options.

The total intrinsic value (the amount by which the fair market value exceeds the exercise price) of stock options exercised was $24.5 million and $1.1 million during the three months ended March 31, 2024 and 2023, respectively.

The weighted-average grant-date fair value per share of options granted to employees, non-employees, and directors was $106.92 and $56.86 during the three months ended March 31, 2024 and 2023, respectively.

There was $63.9 million of unrecognized stock-based compensation expense related to employees’, non-employees’, and directors’ options that is expected to be recognized over a weighted-average period of 2.6 years as of March 31, 2024.

Restricted Stock Awards

The following table summarizes the Company’s RSA activity:


	Three Months Ended March 31,
	2024			2023
	Number of Shares	Weighted Average Grant Date Fair Value		Number of Shares	Weighted Average Grant Date Fair Value
Non-vested RSAs, beginning of period	44,400	$	78.89	66,600	$	78.89
Granted	—			—
Vested	(14,523)	$	78.89	(12,649)	$	78.89
Surrendered for taxes	(7,677)	$	78.89	(9,551)	$	78.89
Non-vested RSAs, end of period	22,200	$	78.89	44,400	$	78.89

There was $1.6 million of unrecognized stock-based compensation expense related to employees’ RSAs that is expected to be recognized over a weighted-average period of 11 months as of March 31, 2024.

Restricted Stock Units

The following table summarizes the Company’s RSU activity:


	Three Months Ended March 31,
	2024			2023
	Number of Shares	Weighted Average Grant Date Fair Value		Number of Shares	Weighted Average Grant Date Fair Value
Non-vested RSUs, beginning of period	160,900	$	81.91	—
Granted	223,890	$	159.59	186,900	$	81.91
Vested	(40,075)	$	81.91	—
Forfeited	(14,383)	$	86.27	—
Non-vested RSUs, end of period	330,332	$	134.37	186,900	$	81.91

There was $43.4 million of unrecognized stock-based compensation expense related to employees’ RSU awards that is expected to be recognized over a weighted-average period of 3.7 years as of March 31, 2024.

Performance-Based Restricted Stock Units

The following table summarizes the Company’s PSU activity:


	Three Months Ended March 31,
	2024			2023
	Number of Shares	Weighted Average Grant Date Fair Value		Number of Shares	Weighted Average Grant Date Fair Value
Non-vested PSUs, beginning of period	50,000	$	81.91	—
Granted	112,500	$	159.47	60,000	$	81.91
Vested	(25,000)	$	81.91	—
Forfeited	—			—
Non-vested PSUs, end of period	137,500	$	145.37	60,000	$	81.91

For the three months ended March 31, 2024, the Company granted 112,500 of PSUs, which vest ratably over two years based upon continued service through the vesting date and the achievement of specific regulatory and commercial performance criteria as determined by the Compensation Committee of the Company’s Board of Directors. The performance criteria are to be completed by the end of the year in which the PSU awards were granted. As of the March 31, 2024, the Company estimated that 100% of the newly granted PSUs will be eligible to vest.

There was $19.0 million of unrecognized stock-based compensation expense related to employees’ PSU awards that is expected to be recognized over a weighted-average period of 1.8 years as of March 31, 2024.

Stock-Based Compensation Expense, Net

The Company recorded stock-based compensation expense related to its stock options, RSAs, RSUs, and PSUs in the condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2024 and 2023 as follows:


	Three Months Ended March 31,
(in thousands)	2024		2023
Research and development	$	1,868	$	2,496
Selling, general, and administrative	7,431		7,941
Total stock-based compensation	$	9,299	$	10,437

After the FDA approval of VYJUVEK on May 19, 2023, the Company began capitalizing stock-based compensation associated with the allocation of labor costs related to work performed to manufacture VYJUVEK. For the three months ended March 31, 2024 and 2023, the Company capitalized stock-based compensation of $724 thousand and zero, respectively, into inventory.

Historically, the Company also capitalized the portion of stock-based compensation related to work performed on the construction of our manufacturing facilities. For the three months ended March 31, 2024 and 2023, the Company capitalized stock-based compensation of zero and $162 thousand, respectively, into property and equipment, net.

Stock-Based Compensation - Schedule of Company's Stock Activity (Details) - $ / shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Restricted Stock
Number of Shares
Beginning balance (in shares)	44,400	66,600
Granted (in shares)	0	0
Vested (in shares)	(14,523)	(12,649)
Surrendered for taxes (in shares)	(7,677)	(9,551)
Ending balance (in shares)	22,200	44,400
Weighted Average Grant Date Fair Value
Beginning balance (in dollars per share)	$ 78.89	$ 78.89
Granted (in dollars per share)
Surrendered for taxes (in dollars per share)	78.89	78.89
Ending balance (in dollars per share)	$ 78.89	$ 78.89
Restricted Stock Units (RSUs)
Number of Shares
Beginning balance (in shares)	160,900	0
Granted (in shares)	223,890	186,900
Vested (in shares)	(40,075)	0
Surrendered for taxes (in shares)	(14,383)	0
Ending balance (in shares)	330,332	186,900
Weighted Average Grant Date Fair Value
Beginning balance (in dollars per share)	$ 81.91
Granted (in dollars per share)	159.59	81.91
Vested (in dollars per share)	81.91
Surrendered for taxes (in dollars per share)	86.27
Ending balance (in dollars per share)	$ 134.37	$ 81.91
Performance Shares
Number of Shares
Beginning balance (in shares)	50,000	0
Granted (in shares)	112,500	60,000
Vested (in shares)	(25,000)	0
Surrendered for taxes (in shares)	0	0
Ending balance (in shares)	137,500	60,000
Weighted Average Grant Date Fair Value
Beginning balance (in dollars per share)	$ 81.91
Granted (in dollars per share)	159.47	81.91
Vested (in dollars per share)	81.91
Surrendered for taxes (in dollars per share)
Ending balance (in dollars per share)	$ 145.37	$ 81.91

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2024

Share-Based Payment Arrangement [Abstract]

Schedule of Company's Stock Option Activity

The following table summarizes the Company’s stock option activity for the three months ended March 31, 2024:


	Stock Options Outstanding	Weighted-average Exercise Price		Weighted-average Remaining Contractual Life (in years)	Aggregate Intrinsic Value(1) (in thousands)
Outstanding as of December 31, 2023	2,606,592	$	66.39	7.9	$	150,405
Granted	126,742	$	155.82
Exercised	(259,581)	$	61.52
Cancelled or forfeited	(245,659)	$	67.89

Outstanding as of March 31, 2024	2,228,094	$	71.88	7.7	$	236,279
Exercisable as of March 31, 2024	854,224	$	61.08	6.8	$	99,815

The following table summarizes the Company’s stock option activity for the three months ended March 31, 2023:


	Stock Options Outstanding	Weighted-average Exercise Price		Weighted-average Remaining Contractual Life (in years)	Aggregate Intrinsic Value(1) (in thousands)
Outstanding as of December 31, 2022	3,582,181	$	61.15	8.7	$	64,880
Granted	287,600	$	81.83
Exercised	(42,021)	$	53.54
Cancelled or forfeited	(42,625)	$	65.59

Outstanding as of March 31, 2023	3,785,135	$	62.75	8.5	$	66,066
Exercisable as of March 31, 2023	961,428	$	55.08	7.6	$	24,033

Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity

The following table summarizes the Company’s RSA activity:


	Three Months Ended March 31,
	2024			2023
	Number of Shares	Weighted Average Grant Date Fair Value		Number of Shares	Weighted Average Grant Date Fair Value
Non-vested RSAs, beginning of period	44,400	$	78.89	66,600	$	78.89
Granted	—			—
Vested	(14,523)	$	78.89	(12,649)	$	78.89
Surrendered for taxes	(7,677)	$	78.89	(9,551)	$	78.89
Non-vested RSAs, end of period	22,200	$	78.89	44,400	$	78.89

The following table summarizes the Company’s RSU activity:


	Three Months Ended March 31,
	2024			2023
	Number of Shares	Weighted Average Grant Date Fair Value		Number of Shares	Weighted Average Grant Date Fair Value
Non-vested RSUs, beginning of period	160,900	$	81.91	—
Granted	223,890	$	159.59	186,900	$	81.91
Vested	(40,075)	$	81.91	—
Forfeited	(14,383)	$	86.27	—
Non-vested RSUs, end of period	330,332	$	134.37	186,900	$	81.91

Share-Based Payment Arrangement, Performance Shares, Activity

The following table summarizes the Company’s PSU activity:


	Three Months Ended March 31,
	2024			2023
	Number of Shares	Weighted Average Grant Date Fair Value		Number of Shares	Weighted Average Grant Date Fair Value
Non-vested PSUs, beginning of period	50,000	$	81.91	—
Granted	112,500	$	159.47	60,000	$	81.91
Vested	(25,000)	$	81.91	—
Forfeited	—			—
Non-vested PSUs, end of period	137,500	$	145.37	60,000	$	81.91

Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards


	Three Months Ended March 31,
(in thousands)	2024		2023
Research and development	$	1,868	$	2,496
Selling, general, and administrative	7,431		7,941
Total stock-based compensation	$	9,299	$	10,437

Summary of Significant Accounting Policies (Policies)	3 Months Ended
Summary of Significant Accounting Policies (Policies)	Mar. 31, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”). In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company’s financial position and results of operations for the interim periods presented, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company’s previously reported financial position or results of operations. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (“2023 10-K”), as filed with the U.S. Securities and Exchange Commission (“SEC”) on February 26, 2024.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates in the period these variances become known. Estimates are used in the following areas, among others: variable consideration associated with revenue recognition, stock-based compensation expense, accrued expenses, the fair value of financial instruments and the valuation allowance included in the deferred income tax calculation.
Concentration of Credit Risk and Off-Balance Sheet Risk	Concentration of Credit Risk and Off-Balance Sheet Risk Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents, short-term investments, long-term investments, and accounts receivable, net. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company’s accounts receivable, net and marketable securities, which primarily consist of U.S. government agency securities and treasuries, corporate bonds and commercial paper, potentially subject the Company to concentrations of credit risk.
Off-Balance Sheet Risk	Concentration of Credit Risk and Off-Balance Sheet Risk Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents, short-term investments, long-term investments, and accounts receivable, net. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company’s accounts receivable, net and marketable securities, which primarily consist of U.S. government agency securities and treasuries, corporate bonds and commercial paper, potentially subject the Company to concentrations of credit risk.
Recent Accounting Pronouncements	Recent Accounting Pronouncements There were no accounting pronouncements issued or adopted during the three months ended March 31, 2024 that are expected to have a material impact on the Company’s condensed consolidated financial statements. In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” The purpose of this guidance is to enhance the transparency and usefulness of income tax disclosures and provide comprehensive income tax information, particularly in relation to rate reconciliation and income taxes paid in the U.S. and foreign jurisdictions. This new standard will be effective for fiscal years starting after December 15, 2024, with the option to apply it retrospectively. Early adoption is also allowed. Currently, the Company is assessing the potential impact of this guidance on its consolidated financial statement disclosures.

Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$ 9,299	$ 10,437
Research and development \| Stock Options
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	1,868	2,496
Selling, general, and administrative \| Stock Options
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$ 7,431	$ 7,941

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesThe tax provision for interim periods is calculated using an estimate of the annual effective tax rate, adjusted for discrete items. If there are any changes to the estimated annual tax rate, the Company will make a cumulative adjustment to the income tax provision in the period the change becomes known. The Company did not record an income tax provision for the three months ended March 31, 2024 or 2023 as it generated sufficient tax losses, after consideration of discrete items, during each of the periods.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

+ Details

Balance Sheet Components - Schedule of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 175,132	$ 174,029
Accumulated depreciation	(15,121)	(12,827)
Property and equipment, net	160,011	161,202
Building and building improvements
Property, Plant and Equipment [Line Items]
Total property and equipment	111,232	111,180
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property and equipment	25,363	25,068
Manufacturing equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	25,281	24,905
Construction in progress
Property, Plant and Equipment [Line Items]
Total property and equipment	6,905	7,291
Laboratory equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	3,064	2,339
Computer equipment and software
Property, Plant and Equipment [Line Items]
Total property and equipment	1,647	1,614
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 1,640	$ 1,632

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Agreements with Contract Manufacturing Organizations and Contract Research Organizations The Company enters into various agreements in the normal course of business with Contract Research Organizations (“CROs”), Contract Manufacturing Organizations (“CMOs”) and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. The agreements with CMOs primarily relate to the manufacturing of our sterile gel that is mixed with in-house produced vectors as part of the final drug product for VYJUVEK. Agreements with third parties may also include research and development consulting activities, clinical-trial agreements, storage, packaging, labeling, and/or testing of our pre-commercial and clinical-stage products. The Company is obligated to make milestone payments under certain of these contracts. The Company may also be responsible for the payment of a monthly service fee for project management services for the duration of any agreements. The estimated remaining commitments as of March 31, 2024 under these agreements is approximately $1.1 million. The Company has incurred research and development expenses under these agreements of $1.5 million for the three months ended March 31, 2024 and $2.0 million for the three months ended March 31, 2023. Legal Proceedings In May 2020, a complaint was filed against the Company in the United States District Court for the Western District of Pennsylvania by PeriphaGen, Inc. (“PeriphaGen”) alleging breach of contract and misappropriation of trade secrets. On April 27, 2022, the Company and PeriphaGen entered into a final settlement agreement, and the Company paid PeriphaGen an upfront payment of $25.0 million on April 28, 2022 for: (i) the release of all claims in the trade secret litigation with PeriphaGen; (ii) the acquisition of certain PeriphaGen assets, and (iii) the grant of a license by PeriphaGen for dermatological applications. In accordance with the settlement agreement, on June 15, 2023, the Company paid PeriphaGen an additional $12.5 million following the FDA’s approval of VYJUVEK. The settlement agreement requires the Company to pay three additional $12.5 million contingent milestone payments upon reaching $100.0 million in total cumulative sales, $200.0 million in total cumulative sales and $300.0 million in total cumulative sales. As defined in the settlement agreement, cumulative sales shall include all revenue from sales of the Company’s products by the Company and its affiliates and licensees, as reported by the Company in its annual Form 10-K filings. If all milestones are achieved, the total consideration for settling the dispute, acquiring certain assets, and granting of a license from PeriphaGen will be $75.0 million, of which $37.5 million has been paid. The Company recorded litigation settlement expense of $12.5 million for each of the three months ended March 31, 2024 and 2023 on the condensed consolidated statements of operations and comprehensive loss in accordance with the settlement agreement. During the three months ended March 31, 2024, in accordance with ASC 450, Contingencies (“ASC 450”), the Company determined that reaching $100.0 million in total cumulative sales was probable, and recorded litigation settlement expense of $12.5 million relating to the milestone payment, which becomes payable following the filing of the Annual Report on Form 10-K that reports the $100.0 million in total cumulative sales. The Company recorded litigation settlement expense of $12.5 million for the three months ended March 31, 2023, as it determined that FDA approval of B-VEC was probable. As of March 31, 2024, the Company has not recorded an accrual for the remaining two contingent milestone payments totaling $25.0 million.

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2024	Apr. 29, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	001-38210
Entity Registrant Name	Krystal Biotech, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-1080209
Entity Address, Address Line One	2100 Wharton Street
Entity Address, Address Line Two	Suite 701
Entity Address, City or Town	Pittsburgh
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	15203
City Area Code	412
Local Phone Number	586-5830
Title of 12(b) Security	Common Stock
Trading Symbol	KRYS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		28,558,440
Amendment Flag	false
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001711279
Current Fiscal Year End Date	--12-31